



## ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention

-- ImmusanT will also provide a corporate update --

**CAMBRIDGE, Mass. – May 24, 2018 –** [ImmusanT, Inc.](#), a clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy (ESIT) platform to translate and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases, today announced that Chief Executive Officer, Leslie Williams will participate on a panel and provide a company presentation at the 2018 BIO International Convention, occurring June 4-7, 2018 in Boston, MA.

Ms. Williams and a panel of experts will discuss approaches and advancements made in the non-oncology immunotherapy space. In addition, Ms. Williams will provide a corporate update presentation as the company prepares to enter Phase 2 trials for lead candidate, Nexvax2<sup>®</sup>, a vaccine in development for the treatment of celiac disease.

Details of the panel and presentation are as follows:

**Panel Title:** Immuno\_\_\_\_\_ (Fill in the Blank) – Translating Immunological Insights from Oncology to Other Disease Areas

**Date:** Tuesday, Jun 5, 2018

**Time:** 1:45 PM–2:45 PM ET

**Location:** Room 210B, Level 2

**Track:** Next Generation Biotherapeutics

**Presentation Date:** Wednesday, June 6, 2018

**Time:** 2:30 PM–2:45 PM ET

**Location:** Company Presentation Theatre 3, Level 0

### **About Nexvax2<sup>®</sup>**

Nexvax2<sup>®</sup> is the most advanced therapeutic approach for celiac disease in clinical development today that targets the fundamental cause of the disease; the loss of immune tolerance to gluten. Nexvax2 is a therapeutic vaccine that reprograms the T-cells responsible for the symptoms of celiac disease to stop triggering a pro-inflammatory response. Nexvax2 intends to protect patients with celiac disease against inadvertent exposure to gluten.

### **About ImmusanT, Inc.**

ImmusanT is a privately held biotechnology company focused on protecting patients with celiac disease against the effects of gluten. By harnessing new discoveries in immunology, ImmusanT aims to improve diagnosis and medical management of celiac disease by protecting against the effects of gluten exposure while patients maintain a gluten-free diet. The company is developing [Nexvax2<sup>®</sup>](#), a therapeutic vaccine for celiac disease, and diagnostic and monitoring tools to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of autoimmune diseases. To learn more about ImmusanT, visit [www.ImmusanT.com](http://www.ImmusanT.com), or follow [ImmusanT](#) on Twitter.

### **Media Contact:**

George E. MacDougall

MacDougall Biomedical Communications

(781) 235-3093  
[george@macbiocom.com](mailto:george@macbiocom.com)

###